JY
JSPRW icon

Jeff Yass’s Japer Therapeutics Warrants JSPRW Stock Holding History

Jeff Yass’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,200
Closed -$618 – 13983
2026
Q1 		$618 Buy
+28,200
New +$911 ﹤0.01% 13040

Other funds holding JSPRW

BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jeff Yass's JSPRW Position: Q2 2026 in Review

Jeff Yass sold out of Japer Therapeutics Warrants (JSPRW) in Q2 2026, closing a stake of 28,200 shares — an estimated $618 sold.

Jeff Yass first reported a position in JSPRW in Q1 2026 and held it in 1 quarter. The position peaked at $618 in Q1 2026. 6 funds tracked by Wall St. Rank hold JSPRW as of Q2 2026.

  • Jeff Yass reported no remaining Japer Therapeutics Warrants position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 28,200 Japer Therapeutics Warrants shares in Q2 2026, an estimated $618.
  • Jeff Yass first reported a position in Japer Therapeutics Warrants in Q1 2026 and held it in 1 quarter.
  • Jeff Yass's Japer Therapeutics Warrants position peaked at $618 in Q1 2026.
  • 6 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.